GlassScriptPhysician profile
Rachna Raman
NPI 1710183710
$3,650.56
in general payments reported to CMS, 2019-2025
19 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.58 · 2021: $2,950 · 2022: $46.74 · 2023: $507 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.78 |
| Education | $130.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,713.00 | 2021 | |
| Exelixis INC. | $1,225.00 | 2021 | |
| Astellas Pharma US INC | $124.07 | 2023 | Xospata |
| Caris Mpi, INC. | $91.81 | 2025 | Mi Cancer Seek |
| Seagen INC. | $72.52 | 2019-2023 | Padcev |
| Pfizer INC. | $64.56 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $59.51 | 2023 | |
| Eisai INC. | $44.20 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $41.59 | 2023 | Lynparza |
| Beigene USA, INC. | $37.20 | 2023 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $35.38 | 2022-2023 | Opdivo |
| Mylan Institutional INC. | $26.06 | 2023 | Fulphila, Ogivri |
| Incyte Corporation | $24.63 | 2023 | Jakafi |
| Abbvie INC. | $22.92 | 2023 | |
| Array Biopharma INC | $20.15 | 2023 | Braftovi, Lorbrena, Mektovi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $19.23 | 2023 | Libtayo |
| G1 Therapeutics, INC. | $16.91 | 2023 | Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $11.82 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachna Raman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.